Rigel Pharmaceuticals | RIGL - DEBITO





DEBITO Cambiamento Data
Agenus USD 35.54M 2.34M 2025-03
Amgen USD 57.32B 2.72B 2026-03
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 983.69M 5.77M 2026-06
AstraZeneca USD 32.24B 1.68B 2026-06
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 46.43B 711M 2026-03
Celldex Therapeutics USD 1.91M 428K 2026-03
Daiichi Sankyo JPY 300.48B 99.34B 2026-03
Eli Lilly USD 43.37B 867M 2026-03
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Heron Therapeutics USD 149.65M 157K 2024-09
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 1.91B 425.5M 2026-06
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 451.98M 486K 2026-03
MacroGenics USD 36.51M 500K 2026-03
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Pfizer USD 63.19B 536M 2026-06
Regeneron Pharmaceuticals USD 2.71B 400K 2026-06
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sangamo BioSciences USD 0 0 2022-06
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Veracyte USD 39.33M 321K 2026-03